Author

Douglas C. Wolf 1

1 Atlanta Gastroenterology Associates ,Atlanta,United States

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF OZANIMOD, AN ORAL S1P RECEPTOR MODULATOR, IN MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS OF THE MAINTENANCE PERIOD OF THE TOUCHSTONE STUDY

William Sandborn, Brian G. Feagan, Douglas C. Wolf, Geert R. D'Haens, Severine Vermeire, Stephen B Hanauer, Subrata Ghosh, Heather Smith, Matt Cravets, Paul A. Frohna, Richard Aranda, Sheila Gujrathi, Allan Olson

CHARACTERISTICS OF ULCERATIVE COLITIS PATIENTS BY URGENCY OF DEFECATION AT ENROLLMENT IN THE CORRONA INFLAMMATORY BOWEL DISEASE REGISTRY

Douglas C. Wolf

CHARACTERISTICS OF ULCERATIVE COLITIS PATIENTS BY URGENCY OF DEFECATION AT ENROLLMENT IN THE CORRONA INFLAMMATORY BOWEL DISEASE REGISTRY

Douglas C. Wolf, April Naegeli, Mingyang Shan, Theresa Hunter Gibble, Angelina Sontag, Page Moore, Rachel Mackey, Margaux Crabtree, Raymond Cross

CLINICAL BENEFIT OF ADALIMUMAB DOSE ADJUSTMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE IN EXTEND

Jean-Frederic Colombel, Paul Rutgeerts, William Sandborn, Douglas C. Wolf, Walter Reinisch, Gert Van Assche, Samantha Eichner, Joel Petersson, Anne M. Robinson, Roopal B Thakkar

Clinical Remission Demonstrated with Oral Ozanimod in the Overall Population and Across Multiple Subgroups of Patients with Moderately to Severely Active Ulcerative Colitis in the TOUCHSTONE Trial

Brian G. Feagan, William Sandborn, Geert R. D'Haens, Steve Hanauer, Douglas C. Wolf, Severine Vermeire, Subrata Ghosh, Annkatrin Petersen Jappelli, Steven Ye Hua, Kevin Shan, W Jerry Liu

EFFECTS OF OZANIMOD ON CIRCULATING LYMPHOCYTES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: FLOW CYTOMETRY RESULTS FROM THE STEPSTONE PHASE 2 STUDY

Sarah Harris, William Sandborn, Brian G. Feagan, Stephen B Hanauer, Severine Vermeire, Subrata Ghosh, Wenzhong Liu, Douglas C. Wolf, Geert D’Haens

EFFICACY OF USTEKINUMAB FOR INDUCTION AND MAINTENANCE OF ENDOSCOPIC HEALING IN PATIENTS WITH CROHN?S DISEASE

Paul Rutgeerts, Christopher Gasink, Daphne Chan, Yinghua Lang, Paul Pollack, Stephen B Hanauer, Douglas C. Wolf, Douglas Jacobstein, Jewel Johanns, Philippe Szapary, Brian G. Feagan, William Sandborn

ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR BIOLOGIC/JANUS KINASE INHIBITOR-NAÏVE AND -EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Brian G. Feagan, Laurent Peyrin-Biroulet, William J. Sandborn, Geert R. D'Haens, Julian Panés, Andres Yarur, Douglas C. Wolf, Timothy Ritter, Stefan Schreiber, Sheldon Sloan, Fabio Cataldi, Kevin Shan, Christopher J. Rabbat, Michael Chiorean, Filip Baert, Bruce E. Sands, Marla C. Dubinsky, Severine Vermeire, Martina Goets

ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

William J. Sandborn, Severine Vermeire, Laurent Peyrin-Biroulet, Marla C. Dubinsky, Julian Panés, Andres Yarur, Timothy Ritter, Filip Baert, Stefan Schreiber, Sheldon Sloan, Fabio Cataldi, Kevin Shan, Christopher J. Rabbat, Michael Chiorean, Douglas C. Wolf, Bruce E. Sands, Geert R. D'Haens, Silvio Danese, Martina Goetsch

LONG-TERM SAFETY AND EFFICACY OF OZANIMOD IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE TOUCHSTONE OPEN-LABEL EXTENSION

William Sandborn, Brian G. Feagan, Stephen B Hanauer, Severine Vermeire, Subrata Ghosh, Wenzhong Liu, AnnKatrin Petersen, Lorna Charles, Vivian Huang, Keith Usiskin, Douglas C. Wolf, Geert R. D'Haens

Item 1 - 10 / 16
1
2